|
|
|
14.05.26 - 19:36
|
Is Eli Lilly Going To $1,100? (24/7 Wall St.)
|
|
|
Eli Lilly (NYSE:LLY) just delivered one of the most impressive quarters in big pharma history, and the stock is responding. After a sharp drawdown in early 2026, shares have rebounded 9.27% over the past month as Mounjaro and Zepbound continue to redefine the obesity and diabetes treatment landscape. Our 24/7 Wall St. price target points ... Is Eli Lilly Going To $1,100?...
|
|
|
|
|
14.05.26 - 12:45
|
Eli Lilly-Aktie kurz vor neuem Allzeithoch? (Sharedeals)
|
|
|
Eli Lilly gehört weiterhin zu den stärksten Wachstumsunternehmen am gesamten US Aktienmarkt. Nach den aktuellen Quartalszahlen richtet sich der Blick der Anleger nun vor allem auf die charttechnisch wichtige Marke von 1.000 US$. Eli Lilly überzeugt mit starkem Wachstum Eli Lilly and Company konnte mit den aktuellen Quartalszahlen erneut die Erwartungen der Märkte übertreffen. Der […]
The post Eli Lilly-Aktie kurz vor neuem Allzeithoch? first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
13.05.26 - 11:42
|
Novo Nordisk: Aufholjagd geht weiter – Punktgewinn gegen Eli Lilly (Der Aktionaer)
|
|
|
Bei der Aktie des dänischen Adipositas-Spezialisten Novo Nordisk geht es weiter aufwärts. Die Aktie hat heute bei 300 dänischen Kronen eine psychologisch wichtige Hürde geknackt. Damit rücken weitere wichtige Marken immer näher. Unterstützung erhält das Papier von guten Daten, bei denen Novo Nordisk auch im Vergleich zum US-Konkurrenten Eli Lilly punkten kann....
|
|
|
12.05.26 - 19:45
|
GLP-1 Wars: Winners & Losers (Zacks)
|
|
|
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market....
|
|
|
|
|
12.05.26 - 17:30
|
Eli Lilly Price Prediction: This Is Where The Stock Will End This Year (24/7 Wall St.)
|
|
|
Few stocks have polarized investors in 2026 like Eli Lilly (NYSE:LLY). After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of fundamentals. Here is where I land on the $1,000 debate. The 24/7 Wall St. Price Target for Eli Lilly Eli Lilly trades at $948.45 as ... Eli Lilly Price Prediction: This Is Where The Stock Will End This Year...
|
|
|
12.05.26 - 14:33
|
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook (ZeroHedge)
|
|
|
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook
Hims & Hers shares tumbled in premarket trading in New York, the most in three months, after the company posted a first-quarter loss and revenue that missed analyst estimates tracked by Bloomberg, as costs rose amid a massive pivot from selling copycat GLP-1 drugs toward branded obesity drugs from Novo Nordisk and Eli Lilly.
Revenue for the first quarter came in at $608 million versus the $617.5 million Bloomberg Consensus estimate, while the telehealth firm swung to a loss of 40 cents a share from a 20-cent profit a year earlier.
HIMS recorded $33.5 million in restructuring charges, including inventory write-downs and transition costs.
"This was an incredibly valuable transition," HIMS CEO Andrew Dudum told analysts on an earnings call. "We are seeing adoption and weight-loss near-record levels, even beyond the demand we saw following this year's New Year's and Super Bowl campaigns."
Here's a snapshot o...
|
|
|
12.05.26 - 13:42
|
Lilly Bounces Into ‘Sell in May’ Territory as Pricing Pressures Loom (24/7 Wall St.)
|
|
|
The market adage “Sell in May and Go Away” rarely fits a single name cleanly. Eli Lilly (NYSE: LLY) is an unusual exception this spring. The GLP-1 leader has ripped higher off its post-earnings lows yet remains underwater for the year, an asymmetric setup that draws seasonal traders toward a tactical trim. The Setup: A ... Lilly Bounces Into 'Sell in May' Territory as Pricing Pressures Loom...
|
|
|
12.05.26 - 07:03
|
Roche receives CE mark for new blood test to detect Alzheimer′s pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217) (GlobeNewswire EN)
|
|
|
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and designed to measure the phosphorylated Tau (pTau) 217 protein, an indicator of amyloid pathology and a hallmark of Alzheimer's disease.1,2,4,7,8 The same cutoffs (high and low) of the blood test can be used across primary and secondary care settings, to rule in or rule out amyloid pathology in people presenting with symptoms or complaints of cognitive decline.1,2,4,5 The early detection of the amyloid pathology is critical for Alzheimer's diagnosis and treatment, as it enables individuals, families, and caregivers to understand the cause of symptoms, access appropriate care, and actively contribute to the planning of next steps.3,4,5,9,10...
|
|
|
|
|
|
|
11.05.26 - 15:06
|
Pfizer vs Eli Lilly: Different Bets on Pharma M&A (24/7 Wall St.)
|
|
|
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly's Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
